Founded by cardiologists, Cardiovascular Clinical Sciences is a full-service CRO providing the highest level of clinical trial execution via integration of medical, site, and patient perspectives. CCS facilitates innovation and improves patient outcomes through cardiovascular therapeutics and diagnostics expertise –driven by accessible leadership, staff continuity, and global reach. CCS has significant experience designing and executing trials in HFpEF Patients:
- Executing >2 heart failure trials/year since 1997
- Collaborating with regulators on novel adaptive designs
- Optimizing enrollment without sacrificing data quality
Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH, dyslipidemia, inflammation, diabetic nephropathy, HFpEF and atherosclerosis.
For >15 years, we have been evaluating the efficacy of our clients' drugs using gold-standard and radio-tracer based experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners.
AnaBios’ advanced human tissue-based methods enable a unique approach that integrates data from human ex vivo studies with preclinical animal data. We have developed the ability to test the potential efficacy and safety of new drug compounds in human tissues well in advance of clinical trials. This is made possible by a network of partnering U.S. hospitals, the utilization of proprietary tissue preservation methods and lab-based assessment of drug effects on human tissues and isolated cells. From hospital to laboratory, AnaBios maintains full oversight of the recovery process and utilization of human tissues to guarantee consistency in tissue viability.
Nordic Bioscience has more than 25 years’ experience in biomarker development and integrating these biomarkers into clinical trials with extensive scientific expertise in the fields of cardiovascular, fibrosis, immunoscience and oncology.
Using our unique biomarker technology, we identify predictive and prognostic biomarkers which are used to enrich clinical trials and may reduce trial length and size required to determine therapeutic efficacy.
With over 550 publications in leading journals, we pride ourselves with our highly scientific approach and mindset.
Welcome to the Biomarker Powerhouse!